戻る
Cidara Therapeutics Inc (CDTX)価格
CDTX 株価推移チャート
CDTX 収入
Cidara Therapeutics Inc
$221.38
0%
$0
本日現在の状況：Jan 21, 14:25:09 GMT-5
最新の利益結果: Q3 '25
報告済み: 2025-11-06
歴史的収益
四半期
年次
EPS
収入
Earnings FAQ
CDTXの最近の1株当たり利益（EPS）は予想と比較してどうでしたか？
Cidara Therapeutics Inc CDTXの前四半期の収益はどうでしたか？
Cidara Therapeutics Incの収益見積もりはいくらですか？
Cidara Therapeutics Incの収益品質スコアはどれくらいですか？
Cidara Therapeutics Incはいつ収益を報告しますか？
Cidara Therapeutics Incの予想収益はいくらですか？
Cidara Therapeutics Incは収益予想を上回りましたか？
主要データ
前終値
$221.38
始値
$221.09
当日レンジ
$221.28 - $221.41
52週レンジ
$15.22 - $221.42
取引高
2.6M
平均取引高
1.3M
1株当たり利益(TTM)
-11.77
配当利回り
--
時価総額
$6.9B
CDTXとは何ですか？
Cidara Therapeutics, Inc. engages in developing targeted immunotherapies designed to save lives and improve the standard of care for patients facing serious diseases. The company is headquartered in San Diego, California. The company went IPO on 2015-04-15. The firm is using its Cloudbreak platform to develop drug-Fc conjugate (DFC), immunotherapies designed to save lives and improve the standard of care for patients facing serious diseases. The Company’s Cloudbreak platform enables development of DFCs that inhibit specific disease targets while simultaneously engaging the immune system. The Company’s lead DFC candidate CD388, is a highly potent antiviral designed to deliver universal prevention and treatment of seasonal and pandemic influenza, which has completed Phase I and Phase IIa clinical trials. Its oncology DFC candidate, CBO421, is a development candidate targeting CD73 for the treatment of solid tumors. Its Cloudbreak platform creates single molecule cocktails by coupling targeted small molecules and peptides to a human antibody fragment (Fc). The firm is also advancing multiple preclinical and discovery programs targeting cancer and autoimmune diseases.